European Industry Proposes Incentive To Develop New Antimicrobials
EFPIA Urges Care Over Definition Of ‘Unmet Medical Need’
Executive Summary
With proposals for an overhaul of the EU medicines legislation due at the end of this year, EFPIA has published its formal response to the European Commission’s consultation with suggestions for facilitating new antibiotic development, testing new regulatory approaches to novel medicines, and tackling medicine shortages.
You may also be interested in...
EMA Aligns Antibiotics Guideline To Help Facilitate Global Trials
The EU regulator says it supports a globally aligned approach to the development of new antimicrobial medicines.
Coronavirus Notebook: Richer Countries Urged To Pay ‘Fair Share’ Of Vaccine & Drug Financing, EU Assesses Comirnaty Boosters
EFPIA has welcomed an evidence-based report on the regulatory flexibilities used in Europe during the pandemic and how they could be further employed in future. The EMA’s drug safety committee is looking at more reports of menstrual disorders with mRNA vaccines.
From Innovation Mindsets To Incentives And COVID-19 Lessons: How EU Pharma Legislation Should Evolve
If the EU wants to become a more competitive space for innovation it can take a few lessons from both the US and the COVID-10 pandemic, say European pharma industry representatives. Fostering better communication between regulators and companies is just one example.